Topics

FDA lifts partial hold on Xencor leukemia study

10:10 EDT 30 Apr 2019 | MedCity News

T-cells attacking cancer cell illustration of microscopic photosT-cells attacking cancer cell illustration of microscopic photos

The hold had been placed in February following two deaths in the study, including one in a patient who experienced cytokine release syndrome. The company has amended the trial protocol to mandate monitoring and management of CRS.

Original Article: FDA lifts partial hold on Xencor leukemia study

NEXT ARTICLE

More From BioPortfolio on "FDA lifts partial hold on Xencor leukemia study"

Quick Search

Relevant Topic

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...